Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOR106 Phase 1 in Healthy Volunteers and Atopic Dermatitis
NCT03689829Phase 1Terminated
- Sponsor
- Galapagos NV
- Start
- Aug 2018
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of MOR106 in atopic dermatitis (AD) (8 arms), sponsored by Galapagos NV. Primary endpoints: Treatment-Emergent Adverse Events at Day 155, Area Under the Plasma Concentration-Time Curve Ratio at Day 50 and 3 more. Started Aug 2018; status: terminated.
02
Drugs
MOR106
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03689829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03689829.